Late on Monday night in California — 10:30 p.m. PT on October 20 — Galapagos said it intends to wind down its cell-therapy business after a months-long sale process failed to produce a viable buyer. The decision lands as Europe wrestles with an uncomfortable truth: autologous cell therapies are scientifically dazzling but economically awkward — especially under European rules, budgets and labour protections.
What happened — and why it matters
Galapagos’ board (with Gilead-appointed directors recusing) approved an intention to wind down its CAR-T and T-cell therapy operations, subject to works-council consultations in Belgium and the Netherlands.
